UNSPSC 51432801: Saralasin

This classification denotes an antihypertensive agent with the molecular formula C42H65N13O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H2AFV2HE66, chemically known as angiotensin ii, 1-(n-methylglycine)-5-l-valine-8-l-alanine- but generally known as saralasin, which bears US NIH Compound Identifier 36736. European Medicines Agency schedules Saralasin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10447MIG.

UNSPSC 51432801 Saralasin, a Commodity code, encompasses pharmaceutical products for emergency medical and acute care settings that state and local governments procure through direct vendor solicitations and cooperative purchasing vehicles. State and local issuing bodies acquire specific medication formulations—injectable vasodilators, adrenergic agents, and cardiac medications—in quantities ranging from hundreds to thousands of units per contract, with firm pricing inclusive of freight, expiration-date warranties extending nine months or longer, and rapid fulfillment timelines. The City of Tampa, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the mix of issuing bodies active under this code: municipal fire-rescue departments procure life-support medications through sealed competitive bids, state health agencies conduct market research on direct-to-manufacturer pharmacy programs, and multi-state cooperative purchasing entities establish master agreements with pharmaceutical manufacturers for distribution through authorized wholesalers to participating government facilities across multiple jurisdictions.

Recent activity concentrates in Florida, Texas, and Minnesota. The City of Tampa issued IFB No. 26P00188 in April 2026 (response due April 8, 2026) for Advanced Life Support Medications—Labetalol, Epinephrine, Adenosine, and Diltiazem formulations—for use by Tampa Fire Rescue, with an estimated contract value of $40,000 and a one-year base term plus two optional renewals and three 30-day extensions, structured with a Small Local Business Enterprise sheltered-market 5 percent discount. The Texas HHS Commission issued RFI HHS0017013 in March 2026 to solicit vendor capabilities for direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager arrangements, signaling intent to develop a formal RFP thereafter. MMCAP issued RFP S1070000015802 with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers, with contract effectiveness July 1, 2026 and a two-year term, requiring vendors to maintain cGMP and Drug Supply Chain Security Act compliance and accept a 3 percent administrative fee on all purchases.